BioCentury on BioBusiness,
Emerging Company Profile
Allena develops enzymes for hyperoxaluria, linked to kidney stones, GI disorders
Related tables, figures and sidebars
Allena: Degrading in the gut
Monday, December 3, 2012
Pharmaceuticals Inc. is developing a recombinant version of an
undisclosed enzyme that degrades oxalate in the GI tract to treat
hyperoxaluria, a metabolic disease for which there are no therapies. It
believes the enzyme could have manufacturing advantages over the most advanced
competitor, which is a probiotic.
There are two forms of hyperoxaluria. Primary hyperoxaluria is
an autosomal recessive disease affecting 5,000-7,000 patients worldwide.
Hepatic enzyme deficiencies in glyoxylate metabolism lead to increased
endogenous oxalate synthesis and the buildup of calcium oxalate crystals in the
kidneys. Subsequent renal failure occurs in 50% of patients by age 15 and 80%
of patients by age 30, according to The
Oxalosis & Hyperoxaluria Foundation. Those patients will
need kidney and liver transplantation.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]